newsfilter
← Latest News
GlobeNewswire·

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

  • Nkarta, Inc. will host a webcast on Monday, November 9, 2026, at 8:00 a.m. ET to review initial clinical data for its Ntrust program evaluating NKX019 in myositis & systemic sclerosis.
  • The data presentation will occur at the American College of Rheumatology (ACR) Convergence 2026 in Orlando.
  • Registration for the live webcast is available via a provided link, with a replay archived on the Investors section of Nkarta's website.
  • The Ntrust-1 (NCT06557265) & Ntrust-2 (NCT06733935) trials are multi-center, open-label, dose-escalation studies assessing NKX019 safety & potential for durable remission via immune system reset.
  • Leading indications for the trials include myositis & systemic sclerosis, with additional indications covering ANCA-associated vasculitis, rheumatoid arthritis, lupus nephritis, & primary membranous nephropathy.
  • Patients in both studies receive a three-dose cycle of NKX019 following lymphodepletion with fludarabine & cyclophosphamide, or cyclophosphamide alone for those with significant cytopenia.
  • NKX019 is an allogeneic, off-the-shelf immunotherapy using NK cells from healthy donors engineered with a humanized CD19-directed CAR & a proprietary membrane-bound form of interleukin-15.
  • CD19 serves as a biomarker for normal B cells & those implicated in autoimmune disease, which NKX019 targets to eliminate pathogenic B cells.